Evidence map›Paper›PMID 26056021›Full record

Trial reportJournal of bone and mineral metabolism2016

Serum sclerostin and DKK1 in relation to exercise against bone loss in experimental bed rest.

Daniel L Belavý, Natalie Baecker, Gabriele Armbrecht, Gisela Beller, Judith Buehlmeier, Petra Frings-Meuthen, Jörn Rittweger, Heinz J Roth, Martina Heer, Dieter Felsenberg

Abstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Journal of bone and mineral metabolism, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 1 pooled it
3.8field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 1 synthesis or guideline pooled it, 47 citations in OpenAlex.

  1. Pooled it
  2. Denosumab for Prevention of Acute Onset Immobilization-Induced Alterations of Bone Turnover: A Randomized Controlled Trial.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2022
    Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Role of the Osteocyte in Musculoskeletal Disease.Current osteoporosis reports · 2023
    Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 2 countries.

Daniel L BelavýCharité Universitätsmedizin Berlin, Center of Muscle and Bone Research, Hindenburgdamm 30, 12203, Berlin, Germany. belavy@gmail.com.
Natalie BaeckerIEL-Nutrition Physiology, University of Bonn, Endenicher Allee 11-13, 53115, Bonn, Germany.
Gabriele ArmbrechtCharité Universitätsmedizin Berlin, Center of Muscle and Bone Research, Hindenburgdamm 30, 12203, Berlin, Germany.
Gisela BellerCharité Universitätsmedizin Berlin, Center of Muscle and Bone Research, Hindenburgdamm 30, 12203, Berlin, Germany.
Judith BuehlmeierIEL-Nutrition Physiology, University of Bonn, Endenicher Allee 11-13, 53115, Bonn, Germany.
Petra Frings-MeuthenInstitute of Aerospace Medicine, German Aerospace Center, 51147, Cologne, Germany.
Jörn RittwegerInstitute of Aerospace Medicine, German Aerospace Center, 51147, Cologne, Germany.
Heinz J RothLabor Limbach, Abteilung für Endokrinologie und Onkologie, Im Breitspiel 15, 69126, Heidelberg, Germany.
Martina HeerProfil Institut für Stoffwechselforschung GmbH, Hellersbergstr. 9, 41460, Neuss, Germany.
Dieter FelsenbergCharité Universitätsmedizin Berlin, Center of Muscle and Bone Research, Hindenburgdamm 30, 12203, Berlin, Germany.
Charité - Universitätsmedizin Berlin · DEDeutsches Zentrum für Luft- und Raumfahrt e. V. (DLR) · DEDeakin University · AUProfil Institute for Metabolic Research · DEUniversity of Bonn · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The impact of effective exercise against bone loss during experimental bed rest appears to be associated with increases in bone formation rather than reductions of bone resorption. Sclerostin and dickkopf-1 are important inhibitors of osteoblast activity. We hypothesized that exercise in bed rest would prevent increases in sclerostin and dickkopf-1. Twenty-four male subjects performed resistive vibration exercise (RVE; n = 7), resistive exercise only (RE; n = 8), or no exercise (control n = 9) during 60 days of bed rest (2nd Berlin BedRest Study). We measured serum levels of BAP, CTX-I, iPTH, calcium, sclerostin, and dickkopf-1 at 16 time-points during and up to 1 year after bed rest. In inactive control, after an initial increase in both BAP and CTX-I, sclerostin increased. BAP then returned to baseline levels, and CTX-I continued to increase. In RVE and RE, BAP increased more than control in bed rest (p ≤ 0.029). Increases of CTX-I in RE and RVE did not differ significantly to inactive control. RE may have attenuated increases in sclerostin and dickkopf-1, but this was not statistically significant. In RVE there was no evidence for any impact on sclerostin and dickkopf-1 changes. Long-term recovery of bone was also measured and 6-24 months after bed rest, and proximal femur bone mineral content was still greater in RVE than control (p = 0.01). The results, while showing that exercise against bone loss in experimental bed rest results in greater bone formation, could not provide evidence that exercise impeded the rise in serum sclerostin and dickkopf-1 levels.

Indexed as

Bed RestBone DensityExerciseOsteogenesisAdaptor Proteins, Signal TransducingAdultBiomarkersBone Morphogenetic ProteinsFemurGenetic MarkersHumansIntercellular Signaling Peptides and ProteinsMaleTime FactorsAdaptor Proteins, Signal TransducingBiomarkersBone Morphogenetic ProteinsDKK1 protein, humanGenetic MarkersIntercellular Signaling Peptides and ProteinsSOST protein, humanBone mineral densityImmobilisationpQCTSpaceflightTraining

Identifiers

PMID26056021
OpenAlexW1864367510

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.